Latest Complementary Medicine News

BPH Global inks binding deal with Temasek Innovation Holdings to validate its seaweed-based male vitality product through targeted biological assays, advancing regulatory and commercial ambitions.

Anatara Lifesciences delivered ambiguous mechanism of action results for its Anti-Obesity Project while reporting statistically significant weight management effects from compound AOC. The company plans a limited Phase 1 study but may delay it amid ongoing strategic discussions, with cash reserves tightening to $0.7 million.

BPH Global is nearing completion of its novel seaweed-based men’s health supplement, Project Popeye, as it moves toward TGA listing and scientific validation.

Vita Life Sciences has reported a strong FY2025 with record revenue of $93.3 million and net profit after tax rising 18.8%, while declaring a 14.0 cents per share dividend.

Biome Australia Limited has reported a record-breaking quarter and half-year sales performance, driven by strong demand for its clinically-backed probiotic products. Revenue surged over 40% compared to the previous year, defying typical seasonal slowdowns.

Biome Australia Limited has reported a record quarterly revenue of $5.94 million for Q1 FY26, marking a 40% increase year-over-year and its seventh consecutive quarter of positive EBITDA. The company’s strong cash flow and sustained margins underscore its growth momentum.

Biome Australia Limited has reported a record-breaking $5.94 million in sales revenue for Q1 FY26, surpassing forecasts and accelerating toward its ambitious Vision 27 revenue goals.

Biome Australia Limited projects its Q1 FY26 sales revenue to exceed $5.5 million, breaking its previous quarterly record and signaling continued momentum in the microbiome health sector.

ParagonCare Limited reported a solid FY25 with $3.6 billion in revenue and $95.2 million underlying EBITDA, marking progress in its integration and growth strategy across Asia Pacific. The company is poised for further profitability improvements and expansion in FY26.

Anatara Lifesciences has expanded its intellectual property footprint with a 20-year patent granted in Hong Kong for its GaRP gastrointestinal health product, following similar approvals in Europe and Australia. This milestone strengthens its commercial position in the lucrative global market for digestive health solutions.

Biome Australia is expanding its health portfolio with Activated Therapeutics, a new practitioner-only brand launching four evidence-based natural medicine products in Q4 2025.

Nuchev Limited has entered an exclusive sales agency agreement with Brauer Natural Medicines and H&S Brand Corporation, expanding its footprint in Australia's natural and complementary medicines sector. The deal covers key brands including Brauer, Skin Physics, and Rapid Loss, with potential for broader ANZ distribution.